📊 ICCC Key Takeaways
Is Immucell Corp. /DE/ (ICCC) a Good Investment?
ImmuCell shows strong operational trajectory with net income losses shrinking 51.8% YoY and positive free cash flow of $1.2M, supported by a robust balance sheet (4.26x current ratio, 0.34x debt/equity). However, the company remains unprofitable (-3.8% net margin) with modest revenue growth (4.3% YoY) and tight operating margins (6.0%), requiring sustained execution to achieve sustainable profitability.
ImmuCell’s fundamentals are improving: positive operating income and free cash flow with a solid 41% gross margin and strong liquidity indicate a healthier core business despite a small GAAP loss. Moderate leverage and adequate interest coverage provide runway for scaling; sustaining revenue growth and operating leverage should tip results to consistent profitability.
Why Buy Immucell Corp. /DE/ Stock? ICCC Key Strengths
- Exceptional liquidity position with 4.26x current ratio providing substantial financial flexibility
- Positive free cash flow generation ($1.2M) despite net losses, demonstrating underlying operational viability
- Dramatic improvement trajectory in profitability with net income loss declining 51.8% YoY
- Conservative capital structure with 0.34x debt/equity ratio and manageable long-term debt
- Reasonable gross margins at 41.4% indicating product pricing power
- Strong liquidity (4.26x current, 1.93x quick)
- Positive free cash flow (4.4% margin) and operating income
- Healthy gross margin (41.4%) with moderate leverage (0.34x D/E)
ICCC Stock Risks: Immucell Corp. /DE/ Investment Risks
- Company remains unprofitable at net income level with -$1.0M loss, consuming shareholders' capital on accrual basis
- Anemic revenue growth rate of 4.3% YoY insufficient for small-cap diagnostic company in competitive market
- Operating margin of 6.0% leaves minimal buffer for revenue fluctuations or unexpected cost increases
- Limited cash reserves of $3.8M relative to liabilities and operational scale creates funding constraints
- Unproven execution risk—improvement trend must sustain to avoid returning to prior loss levels
- Net losses persist (net margin -3.8%) hurting ROE/ROA
- Modest revenue growth (+4.3% YoY) may limit scale benefits
- Interest coverage only 3.8x; margins sensitive to cost/volume
Key Metrics to Watch
- Path to net profitability and quarterly net income trajectory
- Revenue growth acceleration beyond current 4.3% YoY baseline
- Operating margin expansion given high gross margins suggest room for SG&A optimization
- Cash position adequacy and burn rate sustainability of current free cash flow generation
- Gross margin stability as indicator of competitive positioning in diagnostic market
- Operating margin and sustained FCF generation
- Revenue growth pace and gross margin stability
Immucell Corp. /DE/ (ICCC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 4.4% FCF margin may limit capital allocation flexibility. Strong liquidity with a 4.26x current ratio provides a solid financial cushion.
ICCC Profit Margin, ROE & Profitability Analysis
ICCC vs Healthcare Sector: How Immucell Corp. /DE/ Compares
How Immucell Corp. /DE/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immucell Corp. /DE/ Stock Overvalued? ICCC Valuation Analysis 2026
Based on fundamental analysis, Immucell Corp. /DE/ has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immucell Corp. /DE/ Balance Sheet: ICCC Debt, Cash & Liquidity
ICCC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immucell Corp. /DE/'s revenue has grown significantly by 49% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.26 indicates the company is currently unprofitable.
ICCC Revenue Growth, EPS Growth & YoY Performance
ICCC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.5M | -$139.7K | $-0.02 |
| Q3 2023 | $4.8M | -$655.1K | $-0.08 |
| Q3 2022 | $4.8M | $147.8K | $-0.02 |
| Q2 2018 | $1.7M | -$218.4K | $-0.05 |
| Q1 2018 | $2.9M | -$168.1K | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immucell Corp. /DE/ Dividends, Buybacks & Capital Allocation
ICCC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immucell Corp. /DE/ (CIK: 0000811641)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ICCC
What is the AI rating for ICCC?
Immucell Corp. /DE/ (ICCC) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ICCC's key strengths?
Claude: Exceptional liquidity position with 4.26x current ratio providing substantial financial flexibility. Positive free cash flow generation ($1.2M) despite net losses, demonstrating underlying operational viability. ChatGPT: Strong liquidity (4.26x current, 1.93x quick). Positive free cash flow (4.4% margin) and operating income.
What are the risks of investing in ICCC?
Claude: Company remains unprofitable at net income level with -$1.0M loss, consuming shareholders' capital on accrual basis. Anemic revenue growth rate of 4.3% YoY insufficient for small-cap diagnostic company in competitive market. ChatGPT: Net losses persist (net margin -3.8%) hurting ROE/ROA. Modest revenue growth (+4.3% YoY) may limit scale benefits.
What is ICCC's revenue and growth?
Immucell Corp. /DE/ reported revenue of $27.6M.
Does ICCC pay dividends?
Immucell Corp. /DE/ does not currently pay dividends.
Where can I find ICCC SEC filings?
Official SEC filings for Immucell Corp. /DE/ (CIK: 0000811641) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ICCC's EPS?
Immucell Corp. /DE/ has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ICCC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Immucell Corp. /DE/ has a BUY rating with 70% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ICCC stock overvalued or undervalued?
Valuation metrics for ICCC: ROE of -3.8% (sector avg: 15%), net margin of -3.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ICCC stock in 2026?
Our dual AI analysis gives Immucell Corp. /DE/ a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ICCC's free cash flow?
Immucell Corp. /DE/'s operating cash flow is $2.5M, with capital expenditures of $1.3M. FCF margin is 4.4%.
How does ICCC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3.8% (avg: 12%), ROE -3.8% (avg: 15%), current ratio 4.26 (avg: 2).